Table I.

Association between LRP or survivin expression and clinical characteristics in non-small cell lung cancer.

	Survivin expression, n (%)			LRP expression, n (%)
	−	+	P-value	−	+	P-value
Age, years	55.9±12.3	53.9±10.9	0.557	57.8±11.5	53.4±11.1	0.207
Gender
Male	13 (81.25)	33 (73.30)	0.528	13 (92.86)	33 (70.21)
Female	3 (18.75)	12 (26.67)		1 (7.14)	14 (29.79)
Smoking status
Current or former smokers	7 (43.75)	27 (60.00)	0.261	6 (42.86)	28 (59.57)	0.269
Non-smokers	9 (56.25)	18 (40.00)		8 (57.14)	19 (40.43)
Histology
Squamous cell carcinoma	8 (50.00)	25 (55.56)	0.896	10 (71.43)	23 (48.94)	0.330
Adenocarcinoma	6 (37.50)	14 (31.11)		3 (7.14)	17 (36.17)
Adenosquamous carcinoma	2 (12.50)	6 (13.33)		1 (100.00)	7 (14.89)
Differentiation
Low level	16 (100.00)	37 (82.22)	0.195	14 (100.00)	39 (82.98)	0.254
Medium level	0 (0.00)	7 (15.56)		0 (0.00)	7 (14.89)
High level	0 (0.00)	1 (2.22)		0 (0.00)	1 (2.13)
TNM stage
IIIB	7 (43.75)	14 (31.11)	0.361	8 (57.14)	13 (27.66)	0.042
IV	9 (56.25)	31 (68.89)		6 (42.86)	34 (72.34)
T stage
T1	2 (12.50)	1 (2.22)	0.001	1 (7.14)	2 (4.26)	0.149
T2	3 (18.75)	20 (41.44)		2 (14.29)	21 (44.68)
T3	2 (12.50)	18 (40.00)		5 (35.71)	15 (31.91)
T4	9 (56.25)	6 (13.33)		6 (42.86)	9 (19.15)
N stage
N0	0 (0.00)	3 (6.67)	0.638	1 (7.14)	2 (4.26)	0.952
N1	3 (18.75)	5 (11.11)		2 (14.29)	6 (12.77)
N2	6 (37.50)	19 (42.22)		5 (35.71)	20 (42.55)
N3	7 (43.75)	18 (40.00)		6 (42.86)	19 (40.43)
M stage
M0	7 (43.75)	14 (31.11)	0.361	8 (57.14)	13 (27.66)	0.042
M1	9 (56.25)	31 (68.89)		6 (42.86)	34 (72.34)

TNM, tumor-node-metastasis; LRP, lung resistance protein.